- Home
- AAMI vs ENOV Comparison
AAMI vs ENOV Comparison
Compare AAMI & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- ENOV
- Stock Information
- Founded
- AAMI 1980
- ENOV 1995
- Country
- AAMI United States
- ENOV United States
- Employees
- AAMI N/A
- ENOV N/A
- Industry
- AAMI Investment Managers
- ENOV Fluid Controls
- Sector
- AAMI Finance
- ENOV Industrials
- Exchange
- AAMI Nasdaq
- ENOV Nasdaq
- Market Cap
- AAMI 1.6B
- ENOV 1.8B
- IPO Year
- AAMI N/A
- ENOV 2008
- Fundamental
- Price
- AAMI $49.52
- ENOV $32.86
- Analyst Decision
- AAMI Hold
- ENOV Strong Buy
- Analyst Count
- AAMI 3
- ENOV 6
- Target Price
- AAMI $39.67
- ENOV $51.00
- AVG Volume (30 Days)
- AAMI 206.5K
- ENOV 615.5K
- Earning Date
- AAMI 10-30-2025
- ENOV 11-06-2025
- Dividend Yield
- AAMI 0.08%
- ENOV N/A
- EPS Growth
- AAMI 43.58
- ENOV N/A
- EPS
- AAMI 2.41
- ENOV N/A
- Revenue
- AAMI $538,200,000.00
- ENOV $2,189,576,000.00
- Revenue This Year
- AAMI $21.42
- ENOV $9.13
- Revenue Next Year
- AAMI $19.07
- ENOV $6.39
- P/E Ratio
- AAMI $20.58
- ENOV N/A
- Revenue Growth
- AAMI 18.76
- ENOV 14.40
- 52 Week Low
- AAMI $22.60
- ENOV $25.47
- 52 Week High
- AAMI $51.65
- ENOV $49.83
- Technical
- Relative Strength Index (RSI)
- AAMI 61.32
- ENOV 59.11
- Support Level
- AAMI $47.47
- ENOV $29.00
- Resistance Level
- AAMI $47.78
- ENOV $34.28
- Average True Range (ATR)
- AAMI 1.45
- ENOV 1.10
- MACD
- AAMI 0.38
- ENOV 0.19
- Stochastic Oscillator
- AAMI 90.87
- ENOV 73.11
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About ENOV Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.